ArticleInfection and immunity2009
PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- The Case for Pneumococcal Surface Protein A (PspA): A Comprehensive Review of a Leading Candidate in Pneumococcal Vaccine Research.Vaccines · 2026Review
- Construction and evaluation of an engineered autonomously lysing Salmonella system coupled with self-assembled nanoparticles as a vaccine platform for antigen delivery.Journal of nanobiotechnology · 2026Article
- Current Applications and Immunological Considerations ofMicroorganisms · 2026Review
- Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections.NPJ vaccines · 2024Article
- A Trivalent Live Vaccine Elicits Cross-Species Protection Against Acute Otitis Media in a Murine Model.Vaccines · 2024Article
- A bacterial vesicle-based pneumococcal vaccine against influenza-mediated secondary Streptococcus pneumoniae pulmonary infection.Mucosal immunology · 2024Article
- Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against LethalInfection and immunity · 2022Article
- Protective responses of an engineered PspA recombinant antigen againstBiotechnology reports (Amsterdam, Netherlands) · 2019Article
- A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against LethalInfection and immunity · 2019Article
- Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.Human vaccines & immunotherapeutics · 2019Article
- Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.Infection and immunity · 2017Article
- Rationale and prospects for novel pneumococcal vaccines.Human vaccines & immunotherapeutics · 2016Review
- Expression of periplasmic chaperones in Salmonella Typhimurium reduces its viability in vivo.Current microbiology · 2015Article
- Development ofVaccines · 2014Article
- Promises and pitfalls of live attenuated pneumococcal vaccines.Human vaccines & immunotherapeutics · 2014Article
- Serotype-independent pneumococcal vaccines.Cellular and molecular life sciences : CMLS · 2013Review
- Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.Infection and immunity · 2013Article
- New technologies in developing recombinant attenuated Salmonella vaccine vectors.Microbial pathogenesis · 2013Review
- Panel 6: Vaccines.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2013Review
- Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Pneumococcal surface protein A (PspA) is highly immunogenic and can induce a protective immune response against pneumococcal infection. PspA is divided into two major families based on serological variability: family 1 and family 2. To provide broad protection, PspA proteins from pneumococcal strains Rx1 (family 1) and EF5668 (family 2) were combined to form two PspA fusion proteins, PspA/Rx1-EF5668 and PspA/EF5668-Rx1. Each protein was fused to a type II secretion signal and delivered by a recombinant attenuated Salmonella vaccine (RASV). Both PspA/Rx1-EF5668 and PspA/EF5668-Rx1 were synthesized in the RASV and secreted into the periplasm and supernatant. The fusion proteins reacted strongly with both anti-PspA/Rx1 and anti-PspA/EF5668 antisera. Oral immunization of BALB/c mice with RASV synthesizing either PspA fusion protein elicited serum immunoglobulin G (IgG) and mucosal IgA responses against both families of PspA. Analysis of IgG isotypes (IgG2a and IgG1) indicated a strong Th1 bias to the immune responses to both proteins. Sera from mice immunized with RASV synthesizing PspA/Rx1-EF5668 bound to the surface and directed C3 complement deposition on representative strains from all five PspA clades. Immunization with RASV synthesizing either protein protected mice against intraperitoneal challenge with Streptococcus pneumoniae WU2 strain (family 1), intravenous challenge with S. pneumoniae 3JYP2670 strain (family 2), and intranasal challenge with S. pneumoniae A66.1 (family 1). The PspA/Rx1-EF5668 protein elicited significantly greater protection than PspA/EF5668-Rx1, PspA/Rx1, or PspA/EF5668. These results indicate an RASV synthesizing a PspA fusion protein representing both PspA families constitutes an effective antipneumococcal vaccine, extending and enhancing protection against multiple strains of S. pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.